Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.

Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors? Sex Med (2014) 0.82

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther (2010) 0.81

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Clin Pract (2009) 0.75

A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction. J Korean Med Sci (2017) 0.75

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction. Pharmacy (Basel) (2015) 0.75

Urine cultures from indwelling bladder catheters in nursing home patients: a point prevalence study in a Swedish county. Scand J Urol Nephrol (2011) 1.46

A prospective registration of catheter life and catheter interventions in patients with long-term indwelling urinary catheters. Scand J Urol Nephrol (2011) 1.42

[Testicular torsion--a diagnostic dilemma. Diagnosis confirmed by exploration in only 9 per cent of cases, color ultrasound more accurate]. Lakartidningen (2005) 1.39

[One man of five aged 50 years and over referred to a urologist is diagnosed with cancer. PSA analysis is important for correct prioritization of the referrals]. Lakartidningen (2005) 1.38

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol (2005) 1.25

Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int (2006) 1.12

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol (2006) 1.06

Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol (2002) 0.99

[Sex--only for the rich and healthy? PDE5 inhibitors too expensive for low income men]. Lakartidningen (2006) 0.96

Evaluation of the Swedish version of the Child Drawing: Hospital Manual. J Adv Nurs (2011) 0.96

Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy. Scand J Urol Nephrol (2006) 0.92

Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol (2009) 0.91

Costs of radical cystectomy. Scand J Urol Nephrol (2005) 0.90

Relationship between benign prostatic hyperplasia and lower urinary tract symptoms and correlation between prostate volume and serum prostate-specific antigen in clinical routine. Scand J Urol Nephrol (2005) 0.90

Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int (2008) 0.83

Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. J Sex Med (2009) 0.81

Costs associated with long-term catheter care in nursing home patients. Scand J Urol (2012) 0.80

Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status. J Urol (2002) 0.80

Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. Eur Urol (2006) 0.80

Relationships between lower urinary tract symptoms, the bother they induce and erectile dysfunction. Scand J Urol Nephrol (2006) 0.78

[Uneven quality of referrals for lower urinary tract symptoms in men]. Lakartidningen (2003) 0.77

Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. Drugs (2005) 0.77

Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol (2005) 0.77

Assessing chronic pelvic pain syndrome patients: blood plasma factors and cortisol saliva. Scand J Urol (2013) 0.76

In men with erectile dysfunction, satisfaction with quality of erections correlates with erection hardness, treatment satisfaction, and emotional well-being. J Sex Med (2009) 0.76

[Indwelling catheter--serious problem affecting a smaller group in geriatric residential facilities. An observation study of catheter-related events]. Lakartidningen (2011) 0.75

Urine bladder catheters in nursing home patients: a one-day point prevalence study in a Swedish county. Scand J Urol Nephrol (2010) 0.75

Child drawings and salivary cortisol in children undergoing preoperative procedures associated with day surgery. J Perianesth Nurs (2013) 0.75

Is erectile dysfunction really a clinically useful predictor of cardiovascular disease? Scand J Urol Nephrol (2005) 0.75

Chronic abacterial prostatitis: Living with a troublesome disease affecting many aspects of life. Scand J Urol Nephrol (2008) 0.75

The perioperative dialogue reduces postoperative stress in children undergoing day surgery as confirmed by salivary cortisol. Paediatr Anaesth (2011) 0.75

High-dose rate brachytherapy of prostatic adenocarcinoma in combination with external beam radiotherapy a long-term follow-up of the first 50 patients at one center. Strahlenther Onkol (2002) 0.75

[Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three]. Lakartidningen (2006) 0.75